

RESEARCH ARTICLE

Open Access

Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma



Hongzeng Wu¹, Jinming Zhang¹, Ruoheng Dai², Jianfa Xu¹ and Helin Feng^{1*}

Abstract

Background: Osteosarcoma is aggressive and prognostic biomarkers are important to predict the outcomes of surgery and chemotherapy. Here, we investigated the potential of transferrin receptor-1 (TfR1) and vascular endothelial growth factor (VEGF) as prognostic markers of osteosarcoma.

Methods: TfR1 and VEGF in osteosarcoma samples from a cohort of 53 osteosarcoma patients were detected by immunohistochemistry analysis. The correlation of TfR1 and VEGF levels with clinicopathological parameters was analyzed by Pearson chi-square and Spearman-rho tests. Overall patient survival was analyzed by the Kaplan-Meier method.

Results: We found that TfR1 and VEGF expression levels were low in 20.8% and 18.9%; modest in 35.8% and 35.8%; and high in 43.4% and 45.3% of osteosarcoma patients, respectively. TfR1 and VEGF expression was significantly correlated to histologic grade, Enneking stage, and distant metastasis. TfR1 expression was significantly correlated to VEGF expression and both TfR1 expression and VEGF expression were correlated to shorter overall survival.

Conclusions: TfR1 and VEGF are potential prognostic factors for osteosarcoma.

Keywords: Transferrin receptor-1, VEGF, Prognosis, Osteosarcoma

Background

Primary bone tumors are uncommon and the incidence is low [1]. Osteosarcoma (OS) is a pleomorphic sarcoma of the bone in children and adult, and OS patients frequently develop metastasis [2]. With the recent development of adjuvant chemotherapy, the 5-year-free survival rate has improved to approximately 50% for patient with high-grade OS [3, 4]. The identification of new prognostic biomarkers in osteosarcoma has become increasingly important to predict the responsiveness of treatment [5].

Iron is an element essential to cellular activities such as DNA synthesis and cell proliferation [6–8]. Proteins involved in iron metabolism have been shown to promote lung cancer [9–11]. Recent studies have shown high expression of transferrin receptor-1 (TfR1) in a variety

of tumors including lung, breast, and bladder cancer as well as malignant glioma, but the clinical significance of TfR1 in tumor remains to be confirmed [12, 13].

Angiogenesis plays an important role in tumor development. Vascular endothelial growth factor (VEGF) is known to promote neovascularization [14, 15]. Up to now, the association between TfR1 and VEGF expression and the prognosis of OS patients remains unclear. Therefore, this study aimed to examine TfR1 and VEGF expression in OS patients and analyze their prognostic significance for clinical outcomes of OS.

Methods

Subjects

Ethics Committees of the Fourth Hospital of Hebei Medical University (also named as Tumor Hospital of Hebei Province) approved this study and all patients signed written informed consent. This study enrolled 53 OS patients from 2002 to 2010 from the Fourth Hospital

* Correspondence: fenghelin0311@126.com

¹Department of Orthopedics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang 050011, Hebei, People's Republic of China

Full list of author information is available at the end of the article






Fig. 1 Representative immunohistochemical staining of Tfr1 and VEGF. **a** High expression of Tfr1 in OS. **c** Moderate expression of Tfr1 in OS. **e** Low expression of Tfr1 in OS. **b** High expression of VEGF in OS. **d** Moderate expression of VEGF in OS. **f** Low expression of VEGF in OS. The cells with positive expression were stained brown

of Hebei Medical University, who had not received radiotherapy or chemotherapy. All patient data and follow-up information were collected, including the gender, age, tumor size, histological grade, Enneking stage, and distant metastasis.

Immunohistochemistry analysis

Immunohistochemistry (IHC) analysis was performed on OS tissues using antibodies for Tfr1 (1:100; Biogot Tech) and VEGF (1:100; Santa Cruz Biotechnology),

following a previously described protocol [16]. The results of IHC were judged using the following score system based on the percentage of stained cells, < 1% (0); 1–25% (1); 25–50% (2); 51–80% (3); and > 80% (4); and the intensity of staining, no staining (0); weak staining (1); strong staining (2); and very strong staining (3). The final score was the product of staining intensity and percentage and judged as low (0–3 points), mild (4–7 points), and high (> 7 points).

Table 1 Clinicopathological variables and the expression of Tfr1 and VEGF

		n	Tfr1			P	VEGF			P
			Low(%)	Mild(%)	High(%)		Low(%)	Mild(%)	High(%)	
Sex	Female	25	3(12.0)	10(40.0)	12(48.0)	0.332	5(20.0)	11(44.0)	9(36.0)	0.405
	Male	28	8(28.6)	9(32.1)	11(39.3)		5(17.8)	8(28.6)	15(53.6)	
Age	≥ 20 years	18	4(22.2)	4(22.2)	10(55.6)	0.306	3(16.7)	9(50.0)	6(33.3)	0.293
	< 20 years	35	7(20.0)	15(42.9)	13(37.1)		7(20.0)	10(28.6)	18(51.4)	
Tumor size	< 5 cm	27	6(22.2)	10(37.0)	11(40.8)	0.919	6(22.2)	10(37.0)	11(40.7)	0.741
	≥ 5 cm	26	5(19.2)	9(34.6)	12(46.2)		4(15.4)	9(34.6)	13(50.0)	
Histologic grade*	I	15	4(26.7)	8(53.3)	3(20.0)	0.04	4(26.7)	9(60.0)	2(13.3)	0.02
	II	25	5(20.0)	10(40.0)	10(40.0)		5(20.0)	8(32.0)	12(48.0)	
	III	13	2(15.4)	1(7.7)	10(76.9)		1(7.7)	2(15.4)	10(76.9)	
Distant metastasis*	Yes	23	1(4.2)	11(47.8)	11(47.8)	0.029	1(4.4)	13(56.5)	9(39.1)	0.008
	No	30	10(33.3)	8(26.7)	12(40.0)		9(30.0)	6(20.0)	15(50.0)	
Enneking staging*	I	12	8 (66.7)	3 (25.0)	7(36.9)	< 0.001	6(50.0)	4(33.3)	2(16.7)	0.004
	II	19	2 (10.5)	10(52.6)	21(43.8%)		2(10.5)	10(52.6)	7(36.9)	
	III	22	1 (4.5)	6 (27.3)	15 (68.2)		2(9.1)	5(22.7)	15(68.2)	

Pearson’s chi-squared test was used. *P < 0.05

Table 2 The correlation of Tfr1 and VEGF expression

Characteristics		Tfr1			P (Spearman)
		Low(%)	Mild(%)	High(%)	
VEGF*	Low	10	6(11.3)	3(5.7)	= 0.001
	Mild	19	2(3.7)	10(18.9)	
	High	24	3(5.7)	6(11.3)	
		53	11	19	

Spearman-rho test was used. *P < 0.05

Statistical analysis

All data were analyzed by using SPSS software 25.0. The association of clinical variables was analyzed by the Pearson chi-square test or Spearman-rho test. Univariate and multivariate analyses were performed by using the Cox proportional hazard model. Survival was analyzed by the Kaplan-Meier method. P < 0.05 was considered significant.

Results

Association of Tfr1 and VEGF with clinicopathological parameters

Typical staining of Tfr1 and VEGF in OS tissues was presented in Fig. 1. Tfr1 expression was low in 20.8%, mild in 35.8% and high in 43.4% of OS tissues, whereas VEGF expression was low in 18.9%, mild in 35.8%, and high in 45.3% of OS tissues. As shown in Table 1, Tfr1 and VEGF expression was significantly associated with histological grade, Enneking stage and distant metastasis (all P < 0.05). In addition, Tfr1 and VEGF expression showed a significantly positive correlation (P < 0.01, Table 2).

Tfr1 and VEGF were correlated with poor overall survival of OS patients

Table 3 showed the results of univariate Cox hazard analysis of overall survival of OS patients. Kaplan-Meier survival curve showed that the gender, age, tumor size, and histologic grade had no significance in predicting overall survival, but Enneking staging and distant metastasis predicted a poor overall survival (Fig. 2). Moreover, Tfr1 and VEGF were significantly correlated with poor overall survival (Table 3, Fig. 2).

Tfr1 and VEGF are prognostic factors for OS patients

Table 4 showed the results of multivariate Cox hazard analysis of univariate factors listed in Table 3. Enneking staging, Tfr1 expression, and VEGF expression were identified as independent prognostic factors of OS patients. Higher Tfr1 and VEGF expression, higher Enneking staging, and distance metastasis were associated with significantly higher mortality risk (Plogrank < 0.001) (Fig. 2).

Table 3 Clinicopathological factors associated with overall survival based on univariate Cox proportional regression analysis

Characteristics	Overall survival		P		
	HR	95% CI			
Sex	Female	25	1	0.837	
	Male	28	1.064		0.590–1.919
Age	≥ 20 years	18	1	0.777	
	< 20 years	35	1.093		0.591–2.022
Tumor size	< 5 cm	27	1	0.940	
	≥ 5 cm	26	1.024		0.556–1.884
Histologic grade*	I	15	1	0.412	
	II	25	1.267	0.634–2.534	0.503
	III	13	1.738	0.771–3.917	0.183
Distant metastasis*	Yes	23	1	< 0.001	
	No	30	0.161	0.073–0.356	
Enneking staging*	I	12	1	< 0.001	
	II	19	8.605	2.942–25.169	
	III	22	26.039	7.679–88.293	
Tfr1*	Low	11	1	< 0.001	
	Moderate	19	0.158	0.063–0.398	
	High	23	0.300	0.143–0.629	
VEGF*	Low	10	1	0.021	
	Moderate	19	0.114	0.043–0.303	
	High	24	0.422	0.202–0.880	


HR, hazard ratio; 95% CI, 95% confidence interval. *P < 0.05

Discussion

As a common malignant bone tumor, OS accounts for 30% of all bone malignancies and 3–4% of pediatric tumors [17]. OS has been reported to be the third most common cancer in adolescence [18]. Therefore, it is important to identify novel biomarkers and therapeutic targets for OS.

Abnormal iron metabolism is associated with tumorigenesis [19–21]. Iron homeostasis is maintained by the balance of iron uptake, usage, and storage [22]. Tfr1 is the main protein responsible for iron absorption. Strong immunohistochemical staining of Tfr1 could indicate high cancer cell proliferation and poor prognosis of cancer patients [23–25]. Tumor cells with high Tfr1 expression exhibited a high rate of iron absorption and cell proliferation [26].

To our knowledge, our study was the first to report high expression of Tfr1 and VEGF in OS tissues. Moreover, we found that high Tfr1 and VEGF expression was significantly correlated to histological grade, Enneking staging, and distant metastasis. Furthermore, high Tfr1 and VEGF expression was



significantly correlated to poor overall survival, and both TfR1 and VEGF were independent prognostic indicators of OS patients.

Our study has several limitations. First, immunohistochemistry analysis is only semi-quantitative, and bias may affect the evaluation of staining score although we analyzed all samples in a blind manner. Second, our sample size is limited. Third, our study is a single-center study.

Conclusions

In summary, TfR1 and VEGF expression is high in OS tissues and is correlated to malignancy grade of OS

patients. TfR1 and VEGF are potential prognostic factors of OS patients.

Abbreviations

OS: Osteosarcoma; TfR1: Transferrin receptor-1; VEGF: Vascular endothelial growth factor

Acknowledgements

N/A

Authors' contributions

HF designed the study. JZ, RD, and JX collected the samples and performed the analysis. HW performed the statistical analysis. All authors wrote and approved the final manuscript.

Funding

N/A

Availability of data and materials

All data and material are available upon request

Ethics approval and consent to participate

Ethics Committees of the Fourth Hospital of Hebei Medical University approved this study and all patients signed written informed consent.

Consent for publication

Yes

Competing interests

All authors declare no conflicts of interest.

Table 4 Clinicopathological factors associated with overall survival based on multivariate Cox regression analysis

	Overall survival		
	HR	95% CI	<i>p</i>
Enneking stage	4.622	2.541–8.406	< 0.001
TfR1	2.514	1.445–4.372	0.001
VEGF	2.882	1.203–8.217	0.002

HR, hazard ratio; 95% CI, 95% confidence interval. **P* < 0.05

Author details

¹Department of Orthopedics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang 050011, Hebei, People's Republic of China. ²Department of Pediatrics, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang 050011, Hebei, People's Republic of China.

Received: 19 March 2019 Accepted: 30 July 2019

Published online: 04 September 2019

References

- Franchi A. Epidemiology and classification of bone tumors. *Clin Cases Miner Bone Metab.* 2012;9(2):92–5.
- Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. *Cancer Treat Rev.* 2014;40(4):523–32.
- Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL. Osteosarcoma: a meta-analysis and review of the literature. *Am J Orthop (Belle Mead NJ).* 2015;44(12):547–53.
- Patrascu JM, Vermesan D, Mioc ML, Lazureanu V, Florescu S, Tarullo A, Tatullo M, Abbinante A, Caprio M, Cagiano R, Haragus H. Musculo-skeletal tumors incidence and surgical treatment—a single center 5-year retrospective. *Eur Rev Med Pharmacol Sci.* 2014;18(24):3898–901.
- Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. *Clin Cancer Res.* 2000;6(4):1279–87.
- Torti SV, Torti FM. Ironing out cancer. *Cancer Res.* 2011;71(5):1511–4.
- Arredondo M, Núñez MT. Iron and copper metabolism. *Mol Aspects Med.* 2005;26(4-5):313–27.
- Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. *Proc Natl Acad Sci U S A.* 2006;103(40):14901–6.
- Xiong W, Wang L, Yu F. Regulation of cellular iron metabolism and its implications in lung cancer progression. *Med Oncol.* 2014;31(7):28.
- Chanvorachote P, Luanpitpong S. Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells. *Am J Physiol Cell Physiol.* 2016;310(9):C728–39.
- Zhang C, Zhang F. Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. *Protein Cell.* 2015;6(2):88–100.
- Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. *Clin Immunol.* 2006;121(2):144–58.
- Rosager AM, Sørensen MD, Dahlrøt RH, et al. Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. *PLoS One.* 2017;12(8):e0182954.
- Zhang B, Zhang Y, Zhang X, Lv Y. Suspension state promotes extravasation of breast tumor cells by increasing integrin $\beta 1$ expression. *Biocell.* 2018;42:17–24.
- Zhuang M, Peng Z, Wang J, Su X. Vascular endothelial growth factor gene polymorphisms and gastric cancer risk: a meta-analysis. *J BUON.* 2017;22(3):714–24.
- Huang CC, Michael CW, Pang JC. Fine needle aspiration of primary mediastinal synovial sarcoma: cytomorphologic, immunohistochemical, and molecular study. *Diagn Cytopathol.* 2014;42(2):170–6.
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin.* 2015;65(2):87–108.
- Yağcı-Küpeli B, Akyüz C, Yalçın B, Varan A, Kutluk T, Büyükpamukçu M. Single institution experience on cancer among adolescents 15-19 years of age. *Turk J Pediatr.* 2017;59(1):1–5.
- Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. *N Engl J Med.* 1988;319(16):1047–52.
- Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. *Int J Cancer.* 1994;56(3):364–9.
- Knekt P, Reunanen A, Takkinen H, Aromaa A, Heliövaara M, Hakulinen T. Body iron stores and risk of cancer. *Int J Cancer.* 1994;56(3):379–82.
- Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. *Biochim Biophys Acta.* 1997;1331(1):1–40.
- Faulk WP, Hsi BL, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. *Lancet.* 1980;2(8191):390–2.
- Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. *Lancet.* 1983;1(8323):498–501.
- Wrba F, Ritzinger E, Reiner A, Holzner JH. Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis. An immunohistochemical study. *Virchows Arch A Pathol Anat Histopathol.* 1986;410(1):69–73.
- Calzolari A, Oliviero I, Deaglio S, et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. *Blood Cells Mol Dis.* 2007;39(1):82–91.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

